UK NICE recommends use of Iclusig (ponatinib) in chronic myeloid leukaemia- Incyte

Draft guidelines published by the UK's National Institute for Health and Care Excellence support the use of Iclusig (ponatinib), from Incyte, to treat patients with chronic myeloid leukaemia (CML). The independent appraisal committee has concluded that the drug can be considered a clinical and cost effective use of NHS resources when used to treat these rare forms of the disease, noting that it offers benefits over other treatments such as Pfizer's Bosulif (bosutinib).

In patients with CML, NICE has recommended the use of Iclusig: in adults with chronic phase CML who have the rare T315I mutation; and in those with accelerated or blast phase CML whose disease is resistant to dasatinib or nilotinib, or when they cannot these drugs or for whom imatinib is not clinically appropriate, or when the T315I gene mutation present.